Medics Choice Eye Drops Maximum Redness Relief Solution
NDC Package 55651-059-01
Package Information
Medics Choice Eye Drops Maximum Redness Relief (glycerin, naphazoline hydrochloride) solution is usesFor the relief of redness of the eye due to minor eye irritationsFor the temporary relief of burning and irritation due to dryness of the eyeFor use as a protectant against further irritation or dryness of the eye. This formulation utilizes a solution delivery system. Marketed by K.c. Pharmaceuticals, Inc., this product is identified by NDC 55651-059 and is authorized under FDA application M018.
Identification & Billing
- RxCUI: 1235200 - glycerin 0.5 % / naphazoline HCl 0.03 % Ophthalmic Solution
- RxCUI: 1235200 - glycerin 5 MG/ML / naphazoline hydrochloride 0.3 MG/ML Ophthalmic Solution
- RxCUI: 1235200 - glycerin 0.5 % / naphazoline hydrochloride 0.03 % Ophthalmic Solution
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 55651 - K.c. Pharmaceuticals, Inc.
- 55651-059 - Medics Choice Eye Drops Maximum Redness Relief
- 55651-059-01 - 1 BOTTLE, DROPPER in 1 CARTON / 15 mL in 1 BOTTLE, DROPPER
- 55651-059 - Medics Choice Eye Drops Maximum Redness Relief
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 55651-059-01 identifies a specific commercial package of 1 bottle, dropper in 1 carton / 15 ml in 1 bottle, dropper of Medics Choice Eye Drops Maximum Redness Relief, a human over the counter drug labeled by K.c. Pharmaceuticals, Inc.. This solution is formulated for ophthalmic use and contains glycerin; naphazoline hydrochloride as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by K.c. Pharmaceuticals, Inc. on March 27, 2023. The current certification is valid through December 31, 2026.
How is this K.c. Pharmaceuticals, Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 55651005901. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.